Spectral Medical Inc. (EDTXF)
| Market Cap | 292.66M +73.8% |
| Revenue (ttm) | 1.81M +1.5% |
| Net Income | -25.18M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 1,989.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 1.000 |
| Previous Close | 1.000 |
| Day's Range | 1.000 - 1.000 |
| 52-Week Range | 0.590 - 1.311 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Spectral Medical
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, an... [Read more]
Financial Performance
In 2025, Spectral Medical's revenue was 2.44 million, an increase of 6.82% compared to the previous year's 2.29 million. Losses were -47.69 million, 209.6% more than in 2024.
Financial numbers in CAD Financial StatementsNews
Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update
TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Registration statement: Q2 2026
Spectral Medical filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Spectral Medical Registration statement: Q2 2026
Spectral Medical filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Spectral Medical Earnings release: Q2 2026
Spectral Medical released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Spectral Medical Announces U.S. FDA Filing of PMA Application for PMX
TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders
TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris Trial
100% follow-up achieved for all 157 patients enrolled in the Tigris trial Mortality at 12 months was 52.8% with PMX vs. 66.7% with standard of care alone (absolute risk reduction of 13.9%; number need...
Spectral Medical Announces PMA Submission to U.S. FDA for PMX
TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, to...
Spectral Medical Earnings release: Q1 2026
Spectral Medical released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, to...
Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, will be participating...
Spectral Medical Earnings release: Q4 2025
Spectral Medical released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine
TORONTO and DEERFIELD, Ill., March 24, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shoc...
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Transcript: Status update
Full TIGRIS trial enrollment and strong results have advanced regulatory progress, with PMA submission now targeted for early Q1 2026 following additional FDA feedback. Commercialization plans with Vantive are well underway, and financial resources are sufficient to support operations through late next year.
Spectral Medical Earnings release: Q3 2025
Spectral Medical released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical Announces Publication of EDEN Observational Study
New Study Strengthens Rationale for Spectral's PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group New Study Strengthens Rationale for Spectral's PMX Therapy by Defi...
Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025
TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical Receives US$3 Million From Vantive
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Transcript: Status update
Tigris phase III trial demonstrated significant mortality reduction at 90 days for endotoxic septic shock, with strong efficacy and safety results supporting an FDA submission planned for October. Commercialization efforts with Baxter are progressing, and further data and regulatory milestones are expected in the coming year.
Spectral Medical and Vantive Announce Topline Results from Spectral's Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock
TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and sep...
Spectral Medical Announces Second Quarter and Provides Corporate Update
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Earnings release: Q2 2025
Spectral Medical released its Q2 2025 earnings on August 7, 2025, summarizing the period's financial results.